PAK Signaling Drives Acquired Drug Resistance to MAPK Inhibitors in BRAF-mutant Melanomas

Targeted BRAF inhibition (BRAFi) and combined BRAF and MEK inhibition (BRAFi+MEKi) therapies have significantly improved clinical outcomes in patients with metastatic melanoma. Unfortunately, the efficacy is beset by the acquisition of drug resistance(1–6). Here we investigated molecular mechanisms...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Nature
Κύριοι συγγραφείς: Lu, Hezhe, Liu, Shujing, Zhang, Gao, Wu, Bin, Zhu, Yueyao, Frederick, Dennie T., Hu, Yi, Zhong, Wenqun, Randell, Sergio, Sadek, Norah, Zhang, Wei, Chen, Gang, Cheng, Chaoran, Zeng, Jingwen, Wu, Lawrence W., Zhang, Jie, Liu, Xiaoming, Xu, Wei, Krepler, Clemens, Sproesser, Katrin, Xiao, Min, Miao, Benchun, Liu, Jianglan, Song, Claire D., Liu, Jephrey Y., Karakousis, Giorgos C., Schuchter, Lynn M., Lu, Yiling, Mills, Gordon, Cong, Yusheng, Chernoff, Jonathan, Guo, Jun, Boland, Genevieve M., Sullivan, Ryan J., Wei, Zhi, Field, Jeffrey, Amaravadi, Ravi K., Flaherty, Keith T., Herlyn, Meenhard, Xu, Xiaowei, Guo, Wei
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: 2017
Θέματα:
Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5891348/
https://ncbi.nlm.nih.gov/pubmed/28953887
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nature24040
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια